Polish Multicenter Pulmonary Embolism Response Teams Outcomes Registry

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. The Pulmonary Embolism Response Team (PERT) concept offers a rapid and multidisciplinary approach focused on improving outcomes for patients with PE. All institutionalized PERTs in Poland have been invited to join the study. The goal of this registry is to describe current practice and outcomes in patients with acute PE treated by Polish PERTs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• PE confirmed by computed tomography pulmonary angiography.

• PE symptoms duration ≤ 14 days.

• High-risk PE with hemodynamic instability (one of):

‣ cardiac arrest

⁃ obstructive shock

⁃ persistent hypotension.

• Intermediate-high risk PE patients with right ventricle dysfunction confirmed by imaging studies and elevated troponin level.

Locations
Other Locations
Poland
Poznan University of Medical Sciences
RECRUITING
Poznan
Contact Information
Primary
Aleksander Araszkiewicz
aaraszkiewicz@ump.edu.pl
8549146
Backup
Sylwia Sławek-Szmyt
sylwia.slawek@skpp.edu.pl
8549293
Time Frame
Start Date: 2018-06-01
Estimated Completion Date: 2030-12
Participants
Target number of participants: 10000
Treatments
Intermediate-high risk PE
Confirmed PE causing right ventricle dysfunction confirmed by computed tomography pulmonary angiography or transthoracic echocardiography and elevated troponin level
High-risk PE
Confirmed PE causing hemodynamic instability:~1. Cardiac arrest (need for cardiopulmonary resuscitation) or,~2. Obstructive shock (systolic blood pressure \< 90 mmHg or vasopressors required to achieve a systolic blood pressure ≥90 mmHg despite adequate filling status and end-organ hypoperfusion), or~3. Persistent hypotension (systolic blood pressure \< 90 mmHg for at least 15 minutes)
Related Therapeutic Areas
Sponsors
Leads: Poznan University of Medical Sciences
Collaborators: Polish Cardiac Society

This content was sourced from clinicaltrials.gov